Major Advances in NSCLC: EGFR Exon 20 Insertion Mutations

home / insights / major-advances-in-nsclc-egfr-exon-20-insertion-mutations

Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.

EP. 1: The Evolving Landscape of Molecular Testing for NSCLC

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

October 28th 2021

Experts take a broad look at how molecular profiling has impacted the treatment landscape of non–small cell lung cancer.

EP. 2: NSCLC: Overcoming Barriers to Testing and Molecular Profiling

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

October 28th 2021

Erminia Massarelli, MD, MS, PhD, shares insight on potential barriers to appropriate molecular testing in patients with non–small cell lung cancer.

EP. 3: EGFR Exon 20 Insertion Mutations as a Therapeutic Target in NSCLC

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 4th 2021

In the setting of non–small cell lung cancer, experts consider the importance of EGFR exon 20 insertion mutations as a therapeutic target.

EP. 4: NSCLC: Standard Treatment Approaches for EGFR Exon 20 Insertion Mutations

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 4th 2021

Current standard-of-care approaches toward the management of patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

EP. 5: NSCLC: Amivantamab for Patients With EGFR Exon 20 Insertion Mutations

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 11th 2021

Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.

EP. 6: NSCLC: Mobocertinib for Patients With EGFR Exon 20 Insertion Mutations

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 11th 2021

Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.

EP. 7: Key Differences Between Amivantamab and Mobocertinib in NSCLC

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 18th 2021

Shared insight on the differences between amivantamab and mobocertinib and when they may be appropriately used in patients with NSCLC.

EP. 8: Other Agents Targeting EGFR Exon 20 Insertion Mutations in NSCLC

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 18th 2021

Experts briefly review a number of other agents in NSCLC that target EGFR exon 20 insertion mutations.

EP. 9: NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

Catherine Ann Shu, MD;Erminia Massarelli, MD, PhD

November 25th 2021

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.